Globalizing the biosimilar threat
This article was originally published in Scrip
Biosimilarity is not, it seems, indication specific. European authorities have decided that if a biologic looks like and acts like a different off-patent biologic in one disease, then it will do so in others.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.